ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) – ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.
“Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “We anticipate several important catalysts in the next 12 to 18 months with our evorpacept and ALX2004 clinical programs. Jeff’s leadership will be instrumental in strengthening our development capabilities and operational infrastructure to support high-quality execution and deliver on these upcoming milestones.”
Mr. Knight brings more than 30 years of experience across the biopharmaceutical industry, with demonstrated success advancing programs from early development through commercialization, including multiple oncology programs. Most recently, he served as Chief Development and Operating Officer at Crinetics Pharmaceuticals, where he was responsible for clinical development, portfolio strategy, and corporate operations. Prior to joining Crinetics Pharmaceuticals, Mr. Knight held senior leadership roles at Poseida Therapeutics, Halozyme Therapeutics, Amgen and Onyx Pharmaceuticals, where he led development and operational functions within these organizations. Earlier in his career, he held several roles at Genentech, gaining extensive experience in oncology clinical development and regulatory affairs.
“ALX Oncology is entering a critical phase of growth, with multiple opportunities to advance its pipeline and build a scalable organization,” said Mr. Knight. “I am incredibly excited about ALX’s clinical programs and data and look forward to working with the team to ensure strategic development and operational excellence as the company advances toward key clinical and corporate milestones.”
Mr. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma, as well as a Bachelor of Science in Nursing from the University of Kansas.